For adults with obesity, or with overweight in the presence of at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity.1
Zepbound should not be used for cosmetic
weight loss.1
Zepbound provides options for patients, regardless of insurance status
00:00-00:47
[The Zepbound logo and title animate on screen, followed by the Indications and Limitations of
Use.] CAPTION: HOW TO USE once weekly Zepbound® (tirzepatide)
injection 0.5 mL 2.5 mg | 5
mg | 7.5 mg | 10 mg | 12.5 mg | 15 mg
Indications and Limitations of Use NARRATOR: Indications and Limitations of Use. Zepbound is an injectable prescription
medicine that may help
adults with obesity, or some adults with overweight who also have weight-related medical
problems, to lose excess
body weight and keep the weight off. It may also help adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA. It should be used with a reduced-calorie diet and increased physical activity.
Zepbound contains tirzepatide and should not be used with other tirzepatide-containing
products or any
GLP-1 receptor agonist medicines. It is not known if Zepbound is safe and effective for use in
children.
00:47-01:24
[Select Safety Information animates on screen.] CAPTION: HOW TO USE once weekly Zepbound® (tirzepatide)
injection 0.5 mL 2.5 mg | 5 mg | 7.5 mg | 10 mg | 12.5 mg | 15 mg
Select Safety Information NARRATOR: Select Safety Information. Tell your healthcare provider if you get a lump or
swelling in your
neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid
cancer. In studies
with rats, Zepbound and medicines that work like Zepbound caused thyroid tumors, including
thyroid cancer. It is
not known if Zepbound will cause thyroid tumors, or a type of thyroid cancer called medullary
thyroid carcinoma
(MTC) in people. Do not take Zepbound if you or any of your family have ever had MTC or if you
have an endocrine
system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
01:24-01:29 CAPTION: HOW TO USE once weekly Zepbound® (tirzepatide) injection 0.5 mL 2.5 mg
| 5 mg | 7.5 mg | 10 mg | 12.5 mg | 15 mg NARRATOR: See Indications and Safety Summary with Warnings at the end of this
video.
01:29-01:39
[Title card fades to a woman named Andrea taking a selfie video with her phone as she walks into
her living room.
Upbeat music plays in the background. Andrea shows us the Zepbound box and sits comfortably on
her couch.] CAPTION: Actor portrayal throughout. ANDREA: I just got back from the pharmacy and I bet you’re wondering what’s inside.
Let’s open it
together?
01:39-02:07
[The selfie screen expands to a full, wide screen as Andrea opens the Zepbound box. The box
glows green, lighting up
Andrea’s delighted face as she takes the Zepbound pen out of the box.] CAPTION: 2.5 mg is a starting dose and is not an approved maintenance dose. After 4
weeks, dose should be increased to 5 mg once weekly.
Zepbound should be used along with a reduced-calorie meal plan and increased
physical activity. Individual results may vary. ANDREA: This is the once-weekly, single-use Zepbound pen! You may already know that
Zepbound is proven to
help adults with obesity lose weight along with diet and exercise. So now let's take a look at
how to use the
pen. And if you're like me, you may be nervous to inject for the first time. But don't worry,
I'm here to walk you
through each step of using it.
02:07-02:14
[Andrea holds up the Zepbound pen and looks at a graphic that animates on screen.] CAPTION: Keep it in the refrigerator between 36ºF and 46ºF, not exposed to
freezing temperatures
If Zepbound is stored at room temperature, it should not be returned to the refrigerator. ANDREA: To start, let's talk about how to store Zepbound. It is best to keep it in the
refrigerator.
02:14-02:22
[New text animates on the graphic.] CAPTION: Keep it in its original carton and away from direct light and heat
(safe up to 86ºF)
If Zepbound is stored at room temperature, it should not be returned to the refrigerator. Discard
if not used within 21
days after removing from the refrigerator.
ANDREA: But if you're traveling and don't have access to a fridge, the pens can stay at
room temperature for
up to 21 days. Now, come take a closer look.
02:22-02:31
[In a close-up of the Zepbound pen in Andrea’s hand, a green graphic line traces and highlights
the pen’s cap, then the 2.5 mg label.]
ANDREA: This gray cap stays on until you are ready to inject. Double-check that the pen
is not damaged and
that you’re taking the correct medicine and dose.
02:31-02:39
[The close-up of the Zepbound pen in Andrea's hand remains on screen as a graphic animates
on.] CAPTION: Frozen Cloudy Discolored Particles Expired ANDREA: Don’t use it if the medicine is frozen, cloudy, discolored, or has any
particles. And be sure to
check the expiration date.
02:39-03:00
[Back to a medium shot of Andrea holding the Zepbound pen on her couch as a new graphic
highlighting parts of the body animates on screen.] CAPTION: 1. CHOOSE YOUR INJECTION SITE ANDREA: The first step is to decide where to inject. You can do it in your stomach or
thighs by yourself, or
in the back of your upper arms with someone’s help. You can use the same area every week, just
don’t inject into
the same exact spot. Your doctor can help you with these choices. I'm going for the
stomach.
03:00-03:07
[A hand-washing icon graphic animates on screen.] ANDREA: Oh, and make sure to wash your hands before every injection. Just three more
steps left.
03:07-03:18
[Andrea stands up from the couch and walks to another part of her living room. She watches as a
new graphic showing
a hand pulling the cap from the Zepbound pen animates on. The screen then changes to another
close-up of Andrea holding the Zepbound pen.] CAPTION: 2. PULL OFF THE CAP ANDREA: With the pen locked, remove the gray cap and throw it away. And do not touch the
base.
03:18-03:26
[Andrea places the pen on her stomach and unlocks it as another graphic showing a person placing
the Zepbound pen on their stomach animates on.] CAPTION: 3. PLACE AND UNLOCK ANDREA: Place the clear base of the pen flat against your skin and unlock it by turning
the lock ring.
03:26-03:40
[The camera moves down and zooms in on Andrea’s stomach as she gives herself the injection.
Another graphic showing
a person pushing the button of the Zepbound pen animates on. The pen clicks. After 10 seconds,
it clicks again.
Andrea finishes the injection and holds the pen to the camera while a green graphic line traces
and highlights the
gray plunger.] CAPTION: 4. PRESS AND HOLD UP TO 10 SECONDS ANDREA: Press and hold the purple button for up to 10 seconds. The first click means the
injection has
started. Keep holding. The second click means it’s done. The injection is complete when the
gray plunger is
visible.
03:40-03:56
[Andrea holds the pen up. She then disposes of the pen in an FDA-cleared sharps container before
she picks up her
phone.] ANDREA: And that's all! The process is the same regardless of the dose you've been
prescribed. Now you just
need to safely dispose of your used pen in an FDA-cleared sharps container.
03:56-04:24
[Still filming selfie style, Andrea sets her phone down on a cabinet in her laundry room. She
steps back and picks
up a laundry detergent bottle, gesturing toward different areas of the bottle as she
speaks.] ANDREA: If you don't have an FDA-cleared sharps container, you can use a heavy-duty
plastic household
container, such as a laundry detergent bottle. And no, this isn't a paid partnership with a
detergent brand. Just
make sure it’s made of heavy-duty plastic, has a tight-fitting, puncture-resistant lid, is
leak-resistant, and is
properly labeled.
04:24-04:49
[Suddenly, Andrea’s excited and clumsy dog joins her in the laundry room, bumping into the
cabinet and causing the
phone to fall to the floor. Andrea picks the phone up from the floor, smiles, and pets her dog
as she speaks to the
phone.] ANDREA: Just make sure you leave it in a safe place away from kids and pets! I hope I’ve
helped you feel
comfortable with your Zepbound injection. But if you have more questions, talk to your doctor
or visit
Zepbound.com.
04:49-04:55
[The green Zepbound arrows fly in, wiping on a white title card as the Zepbound logo fades
on.] CAPTION: once weekly Zepbound® (tirzepatide) injection 0.5 mL 2.5 mg | 5 mg |
7.5 mg | 10 mg | 12.5 mg | 15 mg
04:55-13:40
[The Zepbound logo fades out before Important Safety Information fades in and begins to scroll.
Background music plays quietly.] CAPTION: INDICATIONS AND SAFETY SUMMARY WITH WARNINGS
once weekly Zepbound® (tirzepatide) injection 0.5 mL 2.5 mg | 5 mg | 7.5 mg | 10 mg | 12.5 mg |
15 mg NARRATOR: INDICATIONS AND SAFETY SUMMARY WITH WARNINGS. Zepbound is an injectable
prescription medicine that
may help adults with obesity, or some adults with overweight who also have weight-related
medical problems to lose
excess body weight and keep the weight off. It may also help adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA. It should be used with a reduced-calorie diet and increased physical activity.
Zepbound contains tirzepatide and should not be used with other tirzepatide-containing
products or any
GLP-1 receptor agonist medicines. It is not known if Zepbound is safe and effective for use in
children.
Warnings. Zepbound may cause tumors in the thyroid, including thyroid cancer. Watch for
possible symptoms,
such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of
breath. If you have any of
these symptoms, tell your healthcare provider.
Do not use Zepbound if you or any of your family have ever had a type of thyroid cancer
called medullary
thyroid carcinoma (MTC). Do not use Zepbound if you have Multiple Endocrine Neoplasia syndrome
type 2 (MEN 2). Do
not use Zepbound if you have had a serious allergic reaction to tirzepatide or any of the
ingredients in
Zepbound.
Zepbound may cause serious side effects, including:
Severe stomach problems. Stomach problems, sometimes severe, have been reported in
people who use Zepbound.
Tell your healthcare provider if you have stomach problems that are severe or will not go
away.
Kidney problems (kidney failure). Diarrhea, nausea, and vomiting may cause a loss of
fluids (dehydration),
which may cause kidney problems. It is important for you to drink fluids to help reduce your
chance of
dehydration.
Gallbladder problems. Gallbladder problems have happened in some people who use
Zepbound. Tell your
healthcare provider right away if you get symptoms of gallbladder problems, which may include
pain in your upper
stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored
stools.
Inflammation of the pancreas (pancreatitis). Stop using Zepbound and call your
healthcare provider right
away if you have severe pain in your stomach area (abdomen) that will not go away, with or
without vomiting. You
may feel the pain from your abdomen to your back.
Serious allergic reactions. Stop using Zepbound and get medical help right away if you
have any symptoms of
a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems
breathing or
swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.
Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if
you use Zepbound
with medicines that can cause low blood sugar, such as a sulfonylurea or insulin. Signs and
symptoms of low blood
sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache,
blurred vision,
slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger,
weakness or feeling
jittery.
Changes in vision in patients with type 2 diabetes. Tell your healthcare provider if
you have changes in
vision during treatment with Zepbound.
Depression or thoughts of suicide. You should pay attention to changes in your mood,
behaviors, feelings or
thoughts. Call your healthcare provider right away if you have any mental changes that are
new, worse, or worry
you.
Food or liquid getting into the lungs during surgery or other procedures that use
anesthesia or deep
sleepiness (deep sedation). Zepbound may increase the chance of food getting into your lungs
during surgery or
other procedures. Tell all your healthcare providers that you are taking Zepbound before you
are scheduled to have
surgery or other procedures.
Common side effects. The most common side effects of Zepbound include nausea, diarrhea,
vomiting,
constipation, stomach (abdominal) pain, indigestion, injection site reactions, feeling tired,
allergic reactions,
belching, hair loss, and heartburn. These are not all the possible side effects of Zepbound.
Talk to your
healthcare provider about any side effect that bothers you or doesn’t go away.
Tell your doctor if you have any side effects. You can report side effects at
1-800-FDA-1088 or
www.fda.gov/medwatch.
Before using Zepbound. Your healthcare provider should show you how to use Zepbound
before you use it for
the first time. Tell your healthcare provider if you are taking medicines to treat diabetes
including an insulin
or sulfonylurea which could increase your risk of low blood sugar. Talk to your healthcare
provider about low
blood sugar levels and how to manage them. If you take birth control pills by mouth, talk to
your healthcare
provider before you use Zepbound. Birth control pills may not work as well while using
Zepbound. Your healthcare
provider may recommend another type of birth control for 4 weeks after you start Zepbound and
for 4 weeks after
each increase in your dose of Zepbound.
Review these questions with your healthcare provider. Do you have other medical
conditions, including
problems with your pancreas or kidneys, or severe problems with your stomach, such as slowed
emptying of your
stomach (gastroparesis) or problems digesting food? Do you take diabetes medicines, such as
insulin or
sulfonylureas? Do you have a history of diabetic retinopathy? Are you scheduled to have
surgery or other
procedures that use anesthesia or deep sleepiness (deep sedation)? Do you take any other
prescription medicines or
over-the-counter drugs, vitamins, or herbal supplements? Are you pregnant, plan to become
pregnant, breastfeeding,
or plan to breastfeed? Zepbound may harm your unborn baby. Tell your healthcare provider if
you become pregnant
while using Zepbound. It is not known if Zepbound passes into your breast milk. You should
talk with your
healthcare provider about the best way to feed your baby while using Zepbound.
Pregnancy Exposure Registry. There will be a pregnancy exposure registry for women who
have taken Zepbound
during pregnancy. The purpose of this registry is to collect information about the health of
you and your baby.
Talk to your healthcare provider about how you can take part in this registry, or you may
contact Lilly at
1-800-LillyRx (1-800-545-5979).
How to take. Read the Instructions for Use that come with Zepbound. Use Zepbound
exactly as your healthcare
provider says. Use Zepbound with a reduced-calorie diet and increased physical activity.
Zepbound is injected
under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm. Use Zepbound 1
time each week, at
any time of the day. Change (rotate) your injection site with each weekly injection. Do not
use the same site for
each injection. If you take too much Zepbound, call your healthcare provider, seek medical
advice promptly, or
contact a Poison Center expert right away at 1-800-222-1222.
Zepbound injection is approved as a 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL in single-dose pen or single-dose vial.
Learn more. Zepbound is a prescription medicine. For more information, call
1-800-LillyRx (1-800-545-5979)
or go to www.zepbound.lilly.com.
This summary provides basic information about Zepbound but does not include all
information known about
this medicine. Read the information that comes with your prescription each time your
prescription is filled. This
information does not take the place of talking with your healthcare provider. Be sure to talk
to your healthcare
provider about Zepbound and how to take it. Your healthcare provider is the best person to
help you decide if
Zepbound is right for you.
ZP CON BS 20DEC2024
Zepbound® and its delivery device base are registered trademarks owned or licensed by Eli Lilly
and Company, its
subsidiaries, or affiliates.
PP-ZP-US-1484 01/2025
13:40-13:44
[The Zepbound logo fades back in.] CAPTION: once weekly Zepbound® (tirzepatide) injection 0.5 mL 2.5 mg | 5 mg | 7.5 mg | 10 mg |
12.5 mg | 15 mg
A Lilly Medicine
Visit Zepbound.com or call 1-800-LillyRx (1-800-545-5979) for pricing information
Additional strengths of the Zepbound vial are available!
The Zepbound vial (2.5 mg, 5 mg, 7.5 mg, and 10 mg) is available for patients, regardless of
insurance, including Medicare, Medicaid, and no insurance.1
Prescribe
Select Zepbound vial and send to LillyDirect® Self Pay Pharmacy Solutions in EHR.
Available exclusively through LillyDirect® Self Pay Pharmacy Solutions.
Advise patients they will have the option to purchase injection supplies through
LillyDirect® Self Pay Pharmacy Solutions
No prior authorization is needed. Conditions apply, including that patients must certify that they have been prescribed the Zepbound vial for an approved use consistent with FDA-approved product labeling.
Watch how to use the Zepbound vial
00:00-00:46
[The Zepbound logo animates on screen, followed by the Indications and Limitations of Use. Upbeat music plays.]
CAPTION: HOW TO USE once weekly Zepbound® (tirzepatide) injection 0.5 mL 2.5 mg |
5 mg | 7.5 mg | 10 mg | 12.5 mg | 15 mg
Indications and Limitations of Use NARRATOR: Indications and Limitations of Use. Zepbound is an injectable prescription medicine that may
help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose
excess body weight and keep the weight off. It may also help adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA. It should be used with a reduced-calorie diet and increased physical activity.
Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any
GLP-1 receptor agonist medicines. It is not known if Zepbound is safe and effective for use in
children.
00:46-01:23
[Select Safety Information animates on screen.] CAPTION: HOW TO USE once weekly Zepbound® (tirzepatide) injection 0.5 mL 2.5 mg |
5 mg | 7.5 mg | 10 mg | 12.5 mg | 15 mg
Select Safety Information NARRATOR: Select Safety Information. Tell your healthcare provider if you get a lump or swelling in your
neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In
studies with rats, Zepbound and medicines that work like Zepbound caused thyroid tumors, including thyroid
cancer. It is not known if Zepbound will cause thyroid tumors, or a type of thyroid cancer called medullary
thyroid carcinoma (MTC) in people. Do not take Zepbound if you or any of your family have ever had MTC or if you
have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
01:23-01:28 CAPTION: HOW TO USE once weekly Zepbound® (tirzepatide) injection 0.5 mL 2.5 mg |
5 mg | 7.5 mg | 10 mg | 12.5 mg | 15 mg NARRATOR: See Indications and Safety Summary with Warnings at the end of this video.
01:28-01:34 CAPTION: HOW TO USE once weekly Zepbound® (tirzepatide) injection 0.5 mL 2.5 mg |
5 mg | 7.5 mg | 10 mg | 12.5 mg | 15 mg NARRATOR: In this video you will learn how to inject Zepbound using the single-dose vial and a needle and
a syringe.
01:34-01:50
[An illustration of a refrigerator animates on screen. The Zepbound logo appears and remains on screen in the
lower right-hand corner.] CAPTION: Getting started with your Zepbound® (tirzepatide) injection
Read the Instructions for Use before you start taking Zepbound and each time you get a new vial.
Do not share your needles or syringes with other people. You may give other people a serious infection or get a
serious infection from them. NARRATOR: Be sure to read the Instructions for Use before you start taking Zepbound and each time you get
a new vial. There may be new information. This information does not take the place of talking to your healthcare
provider about your medical condition or your treatment.
01:50-01:59
[A carton of Zepbound animates on screen.] CAPTION: Getting started with your Zepbound® (tirzepatide) injection
Read the Instructions for Use before you start taking Zepbound and each time you get a new vial.
Do not share your needles or syringes with other people. You may give other people a serious infection or get a
serious infection from them. NARRATOR: Do not share your needles or syringes with other people. You may give other people a serious
infection or get a serious infection from them.
01:59-02:15
[A carton of Zepbound and vial animate on screen.] CAPTION: Getting started with your Zepbound® (tirzepatide) injection
Read the Instructions for Use before you start taking Zepbound and each time you get a new vial.
Do not share your needles or syringes with other people. You may give other people a serious infection or get a
serious infection from them. NARRATOR: The Zepbound single-dose vial is a subcutaneous injection, which means it is injected under the
skin. Ready to learn how to use the Zepbound single-dose vial? Let’s begin with preparing for your once-weekly
injection.
02:15-02:21
[An illustration of the inside of an open refrigerator door animates on screen, highlighting a carton of Zepbound
on one of the shelves.] CAPTION: Preparing for your Zepbound® injection
• Remove the vial from the refrigerator NARRATOR: Remove the vial from the refrigerator. Remove the single-dose vial from the carton.
02:21-02:29
[The refrigerator illustration fades away as the animation zooms in on a Zepbound vial.] CAPTION: The Zepbound® vial
• Check the medicine and dose
• Check that it has not expired NARRATOR: Check the single-dose vial label to make sure you have the right medicine and dose and that it
has not expired.
02:29-02:39
[A blue line highlights the medicine at the bottom of the Zepbound vial.] CAPTION: The Zepbound® vial
• The medicine is colorless to slightly yellow
• Make sure the medicine is not frozen, not cloudy, and does not have particles in it NARRATOR: Make sure the medicine is colorless to slightly yellow. Make sure the medicine is not frozen,
not cloudy, and does not have particles in it.
02:39-02:57
[In addition to the Zepbound vial, a syringe and needle, an alcohol swab, gauze, and a sharps container animate on
screen.] CAPTION: Preparing for your Zepbound® injection
Gather supplies:
• 1 single-dose Zepbound vial
• 1 syringe and 1 needle, supplied separately
• 1 alcohol swab
• Gauze
• 1 sharps container for throwing away used needles and syringes
The needle and syringe are not included. The needle and syringe recommended by your healthcare
provider may look different than the needle and syringe in this Instructions for Use video. NARRATOR: Gather supplies needed to give your injection. You will need: one single-dose Zepbound vial, one
syringe and one needle (supplied separately), one alcohol swab, gauze, and one sharps container for throwing
away used needles and syringes.
02:57-03:14
[Text animates on screen.] CAPTION: Preparing for your Zepbound® injection
Always use a new syringe and needle for each injection to prevent infections and blocked needles. Do not reuse or
share your syringes or needles with other people. You may give other people a serious infection or get a serious
infection from them. NARRATOR: Always use a new syringe and needle for each injection to prevent infections and blocked
needles. Do not reuse or share your syringes or needles with other people. You may give other people a serious
infection or get a serious infection from them.
We will now review the steps to inject your dose of Zepbound.
03:14-03:19
[A pair of hands move back and forth with bubbles animating in the background.] CAPTION: Preparing for your Zepbound® injection
• Wash your hands NARRATOR: Get ready for your injection by washing your hands with soap and water.
03:19-03:28
[A diagram of a person animates on screen, purple ovals highlighting the stomach area and thighs.] CAPTION: Choose your injection site
• You or someone else can inject Zepbound under the skin of your stomach area (abdomen) or thighs NARRATOR: Choose your injection site. You or someone else can inject Zepbound under the skin of your
stomach area or abdomen or thighs.
03:28-03:45
[Purple ovals highlight the upper arms on the diagram of the person.] CAPTION: Choose your injection site
• Someone else can give you the injection in the back of your upper arm
• Change (rotate) your injection site with each weekly injection. You may use the same area of your body but be
sure to choose a different injection site in that area. Do not use the same site for each injection NARRATOR: You can have another person give you the injection in the back of your upper arm. Change or
rotate your injection site with each weekly injection. You may use the same area of your body, but be sure to
choose a different injection site in that area. Do not use the same site for each injection.
03:45-03:54
[A person’s hands holding a Zepbound vial animate on screen. The hands remove the cap and wipe the rubber stopper
with an alcohol swab.] CAPTION: Prepare the vial
• Pull off the plastic protective cap
• Do not remove the rubber stopper
• Wipe the rubber stopper with the alcohol swab NARRATOR: Begin by pulling off the plastic protective cap, but do not remove the rubber stopper. Wipe the
rubber stopper with an alcohol swab.
03:54-03:59
[The hands remove the outer wrapping from a syringe and needle.] CAPTION: Attach the syringe and needle
• Remove the outer wrapping from the syringe and needle NARRATOR: Next, you will need to remove the outer wrapping from the syringe and needle.
03:59-04:09
[The needle twists onto the syringe until tight and firmly attached.] CAPTION: Attach the syringe and needle
• Remove the outer wrapping from the syringe and needle
• Attach the needle to the top of the syringe NARRATOR: Place the needle on top of the syringe and turn until it is tight and firmly attached. You can
omit this step if the needle and syringe are already attached.
04:09-04:13
[The hands pull the needle shield off the syringe.] CAPTION: Prepare the syringe and needle
• Remove the needle shield by pulling straight off NARRATOR: Now, remove the needle shield by pulling it straight off.
04:13-04:27
[One hand holds the syringe pointing up while the other hand pulls down on the plunger. A graphic animates on
screen, showing a close-up of the syringe and highlighting the plunger tip reaching the 0.5-mL line.] CAPTION: Prepare the syringe and needle
• Hold the syringe pointed up
• Pull down until the plunger tip reaches 0.5 mL of air NARRATOR: Hold the syringe in one hand with the needle pointing up. With the other hand, pull down on the
plunger until the plunger tip reaches the line on the syringe indicating that 0.5 milliliters of air has been
drawn into the syringe.
04:27-04:31
[One hand holds the vial while the other hand pushes the needle through the vial’s rubber stopper.] CAPTION: Push the needle in
• Push the needle through the rubber stopper of the vial NARRATOR: Then, push the needle through the rubber stopper of the vial.
04:31-04:37
[One hand holds the vial while the other hand pushes the plunger all the way into the vial.] CAPTION: Push the plunger in
• Push the needle through the rubber stopper of the vial
• Push the plunger all the way in
• This puts air into the vial NARRATOR: Push the plunger all the way in. This puts air into the vial and makes it easier to pull the
solution from the vial.
04:37-04:50
[One hand holds the vial and syringe upside down. The other hand pulls the plunger down. A graphic animates on
screen, showing a close-up of the syringe and highlighting the plunger tip extending beyond the 0.5-mL line.] CAPTION: Fill the syringe
• Turn the vial and syringe upside down
• Pull the plunger down until the plunger tip is past 0.5 mL
Ensure the tip of the needle is in the liquid in the vial. NARRATOR: Next, you will need to turn the vial and syringe upside down. Make sure that the tip of the
needle is in the liquid and slowly pull the plunger down until the plunger tip is past the 0.5-milliliter
line.
04:50-04:56
[One hand holds the vial and syringe upside down. The other hand flicks the syringe to remove air bubbles.] CAPTION: Fill the syringe
• Tap the syringe if there are any air bubbles NARRATOR: If there are air bubbles, tap the syringe gently a few times to let any air bubbles rise to the
top.
04:56-05:03
[One hand holds the vial and syringe upside down. The other hand pushes the plunger up with its thumb. A graphic
animates on screen, showing a close-up of the syringe and highlighting the plunger tip extending to the 0.5-mL
line.] CAPTION: Finish syringe preparation
• Push the plunger up until the plunger tip reaches 0.5 mL NARRATOR: Then, slowly push the plunger up until the plunger tip reaches the 0.5-milliliter line.
05:03-05:07
[One hand holds the vial. The other hand pulls the syringe out of the vial.] CAPTION: Finish syringe preparation
• Push the plunger up until the plunger tip reaches 0.5 mL
• Pull the syringe out NARRATOR: Pull the syringe out of the rubber stopper of the vial.
05:07-05:19
[The Zepbound logo disappears from the lower right-hand corner. Holding their shirt up to reveal their stomach
area, a person inserts the needle into their skin and pushes down on the plunger of the syringe—holding it in
place for five seconds.] CAPTION: Injecting the medicine
• Insert the needle into your skin
• Push down on the plunger
• The needle should stay in for at least 5 seconds NARRATOR: Now, insert the needle into your skin and push down on the plunger to inject your dose. The
needle should stay in your skin for at least five seconds to make sure you have injected all of your
dose.
05:19-05:31
[The person pulls the needle out of their skin. A sharps container animates on screen. The needle and syringe drop
safely into the container.
The Zepbound logo re-appears on screen in the lower right-hand corner.] CAPTION: Injecting the medicine
• Insert the needle into your skin
• Push down on the plunger
• The needle should stay in for at least 5 seconds
• Pull out the needle
• Do not recap the needle. Recapping the needle can lead to a needle stick injury
• Place the used needle and syringe directly into your FDA-cleared sharps container NARRATOR: Pull the needle out of your skin. Do not recap the needle. Recapping the needle can lead to a
needle stick injury. Place the needle and syringe directly into your sharps container.
05:31-05:41
[Holding their shirt up to reveal their stomach area, the person presses their injection site with an alcohol
swab.
The Zepbound logo disappears from the lower right-hand corner.] CAPTION: Injecting the medicine
• If you see blood, press the injection site with a piece of gauze or alcohol swab
• Do not rub the area NARRATOR: If you see blood after you take the needle out of your skin, press the injection site with a
piece of gauze or an alcohol swab. Do not rub the area.
05:41-05:45
[A sharps container animates on screen. The Zepbound logo re-appears on screen in the lower right-hand
corner.] CAPTION: Disposing of used needles and syringes
• Do not throw away needles and syringes in your household trash NARRATOR: Do not throw away needles and syringes in your household trash.
05:45-06:19
[The sharps container remains on screen. A green hazardous waste label animates on and off screen.] CAPTION: Disposing of used needles and syringes
• If you do not have a sharps disposal container, you may use a household container that is:
• Made of a heavy-duty plastic
• Fit with a puncture-resistant lid that can be closed tightly without sharps being able to come out
• Upright and stable during use
• Leak-resistant
• Properly labeled to warn of hazardous waste inside the container
• Do not recycle your used sharps disposal container
• Keep Zepbound vials, syringes, needles, and all medicines out of the reach of children
NARRATOR: If you do not have an FDA-cleared sharps disposal container, you may use a household container that is
made of a heavy-duty plastic,
fit with a puncture-resistant lid that can be closed tightly without sharps being able to come out, upright and
stable during use, leak-resistant,
and properly labeled to warn of hazardous waste inside the container.
Do not recycle your used sharps disposal container. Follow your community guidelines for the right way to
dispose of your sharps disposal container.
Keep Zepbound vials, syringes, needles, and all medicines out of the reach of children.
06:33-15:21
[Text animates on screen and begins scrolling. The Zepbound logo animates on the upper right-hand corner of the
screen.] CAPTION: INDICATIONS AND SAFETY SUMMARY WITH WARNINGS
once weekly Zepbound® (tirzepatide) injection 0.5 mL 2.5 mg | 5 mg | 7.5 mg | 10 mg | 12.5 mg | 15
mg NARRATOR: INDICATIONS AND SAFETY SUMMARY WITH WARNINGS. Zepbound is an injectable prescription medicine
that may help adults with obesity, or some adults with overweight who also have weight-related medical problems
to lose excess body weight and keep the weight off. It may also help adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA. It should be used with a reduced-calorie diet and increased physical activity.
Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any
GLP-1 receptor agonist medicines. It is not known if Zepbound is safe and effective for use in children.
Warnings. Zepbound may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms,
such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any
of these symptoms, tell your healthcare provider.
Do not use Zepbound if you or any of your family have ever had a type of thyroid cancer called medullary
thyroid carcinoma (MTC). Do not use Zepbound if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Do not use Zepbound if you have had a serious allergic reaction to tirzepatide or any of the ingredients in
Zepbound.
Zepbound may cause serious side effects, including:
Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use
Zepbound. Tell your healthcare provider if you have stomach problems that are severe or will not go away.
Kidney problems (kidney failure). Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration),
which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of
dehydration.
Gallbladder problems. Gallbladder problems have happened in some people who use Zepbound. Tell your
healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper
stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools.
Inflammation of the pancreas (pancreatitis). Stop using Zepbound and call your healthcare provider right
away if you have severe pain in your stomach area (abdomen) that will not go away, with or without vomiting. You
may feel the pain from your abdomen to your back.
Serious allergic reactions. Stop using Zepbound and get medical help right away if you have any symptoms
of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or
swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.
Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Zepbound
with medicines that can cause low blood sugar, such as a sulfonylurea or insulin. Signs and symptoms of low
blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred
vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness or
feeling jittery.
Changes in vision in patients with type 2 diabetes. Tell your healthcare provider if you have changes in
vision during treatment with Zepbound.
Depression or thoughts of suicide. You should pay attention to changes in your mood, behaviors, feelings
or thoughts. Call your healthcare provider right away if you have any mental changes that are new, worse, or
worry you.
Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep
sleepiness (deep sedation). Zepbound may increase the chance of food getting into your lungs during surgery or
other procedures. Tell all your healthcare providers that you are taking Zepbound before you are scheduled to
have surgery or other procedures.
Common side effects. The most common side effects of Zepbound include nausea, diarrhea, vomiting,
constipation, stomach (abdominal) pain, indigestion, injection site reactions, feeling tired, allergic
reactions, belching, hair loss, and heartburn. These are not all the possible side effects of Zepbound. Talk to
your healthcare provider about any side effect that bothers you or doesn’t go away.
Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.
Before using Zepbound. Your healthcare provider should show you how to use Zepbound before you use it for
the first time. Tell your healthcare provider if you are taking medicines to treat diabetes including an insulin
or sulfonylurea which could increase your risk of low blood sugar. Talk to your healthcare provider about low
blood sugar levels and how to manage them. If you take birth control pills by mouth, talk to your healthcare
provider before you use Zepbound. Birth control pills may not work as well while using Zepbound. Your healthcare
provider may recommend another type of birth control for 4 weeks after you start Zepbound and for 4 weeks after
each increase in your dose of Zepbound.
Review these questions with your healthcare provider. Do you have other medical conditions, including
problems with your pancreas or kidneys, or severe problems with your stomach, such as slowed emptying of your
stomach (gastroparesis) or problems digesting food? Do you take diabetes medicines, such as insulin or
sulfonylureas? Do you have a history of diabetic retinopathy? Are you scheduled to have surgery or other
procedures that use anesthesia or deep sleepiness (deep sedation)? Do you take any other prescription medicines
or over-the-counter drugs, vitamins, or herbal supplements? Are you pregnant, plan to become pregnant,
breastfeeding, or plan to breastfeed? Zepbound may harm your unborn baby. Tell your healthcare provider if you
become pregnant while using Zepbound. It is not known if Zepbound passes into your breast milk. You should talk
with your healthcare provider about the best way to feed your baby while using Zepbound.
Pregnancy Exposure Registry. There will be a pregnancy exposure registry for women who have taken Zepbound
during pregnancy. The purpose of this registry is to collect information about the health of you and your baby.
Talk to your healthcare provider about how you can take part in this registry, or you may contact Lilly at
1-800-LillyRx (1-800-545-5979).
How to take. Read the Instructions for Use that come with Zepbound. Use Zepbound exactly as your
healthcare provider says. Use Zepbound with a reduced-calorie diet and increased physical activity. Zepbound is
injected under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm. Use Zepbound 1 time
each week, at any time of the day. Change (rotate) your injection site with each weekly injection. Do not use
the same site for each injection. If you take too much Zepbound, call your healthcare provider, seek medical
advice promptly, or contact a Poison Center expert right away at 1-800-222-1222.
Zepbound injection is approved as a 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL in single-dose pen or single-dose vial.
Learn more. Zepbound is a prescription medicine. For more information, call 1-800-LillyRx (1-800-545-5979)
or go to www.zepbound.lilly.com.
This summary provides basic information about Zepbound but does not include all information known about
this medicine. Read the information that comes with your prescription each time your prescription is filled.
This information does not take the place of talking with your healthcare provider. Be sure to talk to your
healthcare provider about Zepbound and how to take it. Your healthcare provider is the best person to help you
decide if Zepbound is right for you.
ZP CON BS 20DEC2024 Zepbound® and its delivery device base are registered trademarks owned or licensed by Eli
Lilly and Company, its subsidiaries, or affiliates.
15:21-15:24
[The Zepbound logo animates on screen.] CAPTION: once weekly Zepbound® (tirzepatide) injection 0.5 mL 2.5 mg | 5 mg | 7.5 mg | 10 mg | 12.5 mg | 15 mg
A Lilly Medicine
Visit Zepbound.com
or call 1-800-LillyRx (1-800-545-5979) for pricing information
1. Zepbound. Prescribing Information. Lilly USA, LLC.
Important Safety Information for Zepbound® (tirzepatide) injection
Warning:
WARNING: RISK OF THYROID C-CELL
TUMORS
In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Zepbound causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.
Zepbound is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Zepbound and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Zepbound.
Contraindications:
Zepbound is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2, and in patients with known serious hypersensitivity to tirzepatide or any of the excipients in Zepbound. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with tirzepatide.
Risk of Thyroid C-cell Tumors: Counsel patients regarding the potential risk for MTC with the use of Zepbound and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Zepbound. Such monitoring may increase the risk of unnecessary procedures, due to the low test specificity for serum calcitonin and a high background incidence of thyroid disease. Significantly elevated serum calcitonin values may indicate MTC and patients with MTC usually have calcitonin values >50 ng/L. If serum calcitonin is measured and found to be elevated, the patient should be further evaluated. Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated.
Severe Gastrointestinal Adverse Reactions: Use of Zepbound has been associated with gastrointestinal adverse reactions, sometimes severe. In a pool of two Zepbound clinical trials (SURMOUNT-1 and SURMOUNT-2), severe gastrointestinal adverse reactions were reported more frequently among patients receiving Zepbound (5 mg 1.7%, 10 mg 2.5%, 15 mg 3.1%) than placebo (1.0%). Similar rates of severe gastrointestinal adverse reactions were observed in Zepbound clinical trials for weight reduction and in Zepbound clinical trials for obstructive sleep apnea (OSA). Zepbound has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis, and is therefore not recommended in these patients.
Acute Kidney Injury:
Use of Zepbound has been associated with acute kidney injury, which can result from dehydration due to gastrointestinal adverse reactions to Zepbound, including nausea, vomiting, and diarrhea. In patients treated with GLP-1 receptor agonists, there have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis. Some of these events have been reported in patients without known underlying renal disease. A majority of the reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration. Monitor renal function in patients reporting adverse reactions to Zepbound that could lead to volume depletion.
Acute Gallbladder Disease:
Treatment with Zepbound and GLP-1 receptor agonists is associated with an increased occurrence of acute gallbladder disease. In a pool of two clinical trials of Zepbound (SURMOUNT-1 and SURMOUNT-2), cholelithiasis was reported in 1.1% of Zepbound-treated patients and 1.0% of placebo-treated patients, cholecystitis was reported in 0.7% of Zepbound-treated patients and 0.2% of placebo-treated patients, and cholecystectomy was reported in 0.2% of Zepbound-treated patients and no placebo-treated patients. Acute gallbladder events were associated with weight reduction. Similar rates of cholelithiasis were reported in Zepbound clinical trials for weight reduction and in Zepbound trials for OSA. If cholecystitis is suspected, gallbladder diagnostic studies and appropriate clinical follow-up are indicated.
Acute Pancreatitis: Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists or tirzepatide. In clinical trials of tirzepatide for a different indication, 14 events of acute pancreatitis were confirmed by adjudication in 13 tirzepatide-treated patients (0.23 patients per 100 years of exposure) versus 3 events in 3 comparator-treated patients (0.11 patients per 100 years of exposure). In a pool of two Zepbound clinical trials (SURMOUNT-1 and SURMOUNT-2), 0.2% of Zepbound-treated patients had acute pancreatitis confirmed by adjudication (0.14 patients per 100 years of exposure) versus 0.2% of placebo-treated patients (0.15 patients per 100 years of exposure). The exposure-adjusted incidence rate for treatment-emergent adjudication-confirmed pancreatitis in the pooled clinical studies for OSA was 0.84 patients per 100 years for Zepbound and 0 for placebo-treated patients. Observe patients for signs and symptoms of pancreatitis, including persistent severe abdominal pain sometimes radiating to the back, which may or may not be accompanied by vomiting. If pancreatitis is suspected, discontinue Zepbound and initiate appropriate management. Continuation of Zepbound after a confirmed diagnosis of pancreatitis should be individually determined in the clinical judgment of a patient’s health care provider.
Hypersensitivity Reactions: There have been postmarketing reports of serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) in patients treated with tirzepatide. In a pool of two Zepbound clinical trials (SURMOUNT-1 and SURMOUNT-2), 0.1% of Zepbound-treated patients had severe hypersensitivity reactions compared to no placebo-treated patients. Similar rates of severe hypersensitivity reactions were observed in Zepbound clinical trials for weight reduction and in Zepbound trials for OSA. If hypersensitivity reactions occur, advise patients to promptly seek medical attention and discontinue use of Zepbound. Do not use in patients with a previous serious hypersensitivity reaction to tirzepatide or any of the excipients in Zepbound. Use caution in patients with a history of angioedema or anaphylaxis with a GLP-1 receptor agonist because it is unknown if such patients will be predisposed to these reactions with Zepbound.
Hypoglycemia: Zepbound lowers blood glucose and can cause hypoglycemia. In a trial of patients with type 2 diabetes mellitus and BMI ≥27 kg/m2 (Study 2), hypoglycemia (plasma glucose <54 mg/dL) was reported in 4.2% of Zepbound-treated patients versus 1.3% of placebo-treated patients. In this trial, patients taking Zepbound in combination with an insulin secretagogue (e.g., sulfonylurea) had increased risk of hypoglycemia (10.3%) compared to Zepbound-treated patients not taking a sulfonylurea (2.1%). There is also increased risk of hypoglycemia in patients treated with tirzepatide in combination with insulin. Hypoglycemia has also been associated with Zepbound and GLP-1 receptor agonists in adults without type 2 diabetes mellitus. Inform patients of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia. In patients with diabetes mellitus, monitor blood glucose prior to starting Zepbound and during Zepbound treatment. The risk of hypoglycemia may be lowered by a reduction in the dose of insulin or sulfonylurea (or other concomitantly administered insulin secretagogue).
Diabetic Retinopathy Complications in Patients with Type 2 Diabetes Mellitus: Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. Tirzepatide has not been studied in patients with non-proliferative diabetic retinopathy requiring acute therapy, proliferative diabetic retinopathy, or diabetic macular edema. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy.
Suicidal Behavior and Ideation: Suicidal behavior and ideation have been reported in clinical trials with other weight management products. Monitor patients treated with Zepbound for the emergence or worsening of depression, suicidal thoughts or behaviors, and/or any unusual changes in mood or behavior. Discontinue Zepbound in patients who experience suicidal thoughts or behaviors. Avoid Zepbound in patients with a history of suicidal attempts or active suicidal ideation.
Pulmonary Aspiration During General Anesthesia or Deep Sedation: Zepbound delays gastric emptying. There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations. Available data are insufficient to inform recommendations to mitigate the risk of pulmonary aspiration during general anesthesia or deep sedation in patients taking Zepbound, including whether modifying preoperative fasting recommendations or temporarily discontinuing Zepbound could reduce the incidence of retained gastric contents. Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking Zepbound.
Most Common Adverse Reactions: The most common adverse reactions reported in ≥5% of patients treated with Zepbound are nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, eructation, hair loss, and gastroesophageal reflux disease.
Drug Interactions: Zepbound lowers blood glucose. When initiating Zepbound, consider reducing the dose of concomitantly administered insulin or insulin secretagogues (e.g., sulfonylureas) to reduce the risk of hypoglycemia. Zepbound delays gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications. Caution should be exercised when oral medications are concomitantly administered with Zepbound. Monitor patients on oral medications dependent on threshold concentrations for efficacy and those with a narrow therapeutic index (e.g., warfarin) when concomitantly administered with Zepbound.
Pregnancy:
Advise pregnant patients that weight loss is not recommended during pregnancy and to discontinue Zepbound when a pregnancy is recognized. Available data with tirzepatide in pregnant patients are insufficient to evaluate for a drug-related risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Based on animal reproduction studies, there may be risks to the fetus from exposure to tirzepatide during pregnancy. There will be a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Zepbound (tirzepatide) during pregnancy.
Pregnant patients exposed to Zepbound and healthcare providers are
encouraged to contact Eli Lilly and Company at 1-800-LillyRx
(1-800-545-5979).
Lactation:
There are no data on the presence of tirzepatide or its metabolites in animal or human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Zepbound and any potential adverse effects on the breastfed infant from Zepbound or from the underlying maternal condition.
Females and Males of Reproductive Potential:
Use of Zepbound may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying. This delay is largest after the first dose and diminishes over time. Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception, for 4 weeks after initiation with Zepbound and for 4 weeks after each dose escalation.
Pediatric Use: The safety and effectiveness of Zepbound have not been established in pediatric
patients.
Zepbound is available as a 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg injection.
ZP HCP ISI 20DEC2024
INDICATIONS
Zepbound is indicated in combination with a reduced-calorie diet and increased physical activity:
to reduce excess body weight and maintain
weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.
to treat moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity.
Limitations of Use
Zepbound contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.